Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bluma Brenner

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Medecine Sciences : M/S|October 6, 2004
[HIV drug resistance and optimization of antiviral treatment in resource-poor countries]Florence Doualla-Bell, Dan Turner, Hugues Loemba, et al.
Plos One|March 7, 2019
Assessing the role of transmission chains in the spread of HIV-1 among men who have sex with men in Quebec, CanadaLuc Villandré, Aurélie Labbe, Bluma Brenner, et al.
Journal of the International AIDS Society|November 15, 2014
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group MAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.
AIDS (London, England)|September 16, 2015
The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravirMaureen Oliveira, Thibault Mesplède, Daniela Moïsi, et al.
AIDS (London, England)|April 8, 2015
Dolutegravir inhibits HIV-1 Env evolution in primary human cellsThibault Mesplède, Daniela Moïsi, Maureen Oliveira, et al.
AIDS (London, England)|July 2, 2016
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravirMaureen Oliveira, Ruxandra I Ibanescu, Hanh Thi Pham, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2003
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolatesKaridia Diallo, Bluma Brenner, Maureen Oliveira, et al.
AIDS Research and Therapy|January 15, 2017
Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics studyNavaneethan Palanisamy, Nathan Osman, Frédéric Ohnona, et al.
AIDS (London, England)|July 29, 2004
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfectionBluma Brenner, Jean-Pierre Routy, Yudong Quan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infectionDan Turner, Bluma Brenner, Jean-Pierre Routy, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Medecine Sciences : M/S|October 6, 2004
[HIV drug resistance and optimization of antiviral treatment in resource-poor countries]Florence Doualla-Bell, Dan Turner, Hugues Loemba, et al.
Plos One|March 7, 2019
Assessing the role of transmission chains in the spread of HIV-1 among men who have sex with men in Quebec, CanadaLuc Villandré, Aurélie Labbe, Bluma Brenner, et al.
Journal of the International AIDS Society|November 15, 2014
HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group MAgnès Depatureaux, Thibault Mesplède, Peter Quashie, et al.
AIDS (London, England)|September 16, 2015
The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravirMaureen Oliveira, Thibault Mesplède, Daniela Moïsi, et al.
AIDS (London, England)|April 8, 2015
Dolutegravir inhibits HIV-1 Env evolution in primary human cellsThibault Mesplède, Daniela Moïsi, Maureen Oliveira, et al.
AIDS (London, England)|July 2, 2016
The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravirMaureen Oliveira, Ruxandra I Ibanescu, Hanh Thi Pham, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2003
The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolatesKaridia Diallo, Bluma Brenner, Maureen Oliveira, et al.
AIDS Research and Therapy|January 15, 2017
Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics studyNavaneethan Palanisamy, Nathan Osman, Frédéric Ohnona, et al.
AIDS (London, England)|July 29, 2004
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfectionBluma Brenner, Jean-Pierre Routy, Yudong Quan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 4, 2004
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infectionDan Turner, Bluma Brenner, Jean-Pierre Routy, et al.
Pageof 4